December 15, 2025: Ozempic Blindness MDL Is Created for Patients Who Suffered Eye Stroke After Taking GLP-1s Patients diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION) after taking Ozempic, other GLP-1s, can file a lawsuit in the new MDL created for these cases
One section of the warning label links the possibility of AKI to severe dehydration from gastrointestinal distress like vomiting and diarrhea
In a major clinical study called SELECT, involving more than 17,600 participants, people with heart disease who took semaglutide had about a 20% lower risk of heart attack, stroke, or death from heart disease compared to those who did not take it
The Novo Nordisk Foundation Center for Protein Research is supported financially by the Novo Nordisk Foundation (grant number NNF14CC0001)
The primary focus of clinical trials involving semaglutide has been its effectiveness in managing blood sugar levels, promoting weight loss, and improving metabolic health in individuals with type 2 diabetes
